Cannabidiol and periodontal inflammatory disease: A critical assessment

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2022 May;166(2):155-160. doi: 10.5507/bp.2022.012. Epub 2022 Mar 21.


Cannabidiol (CBD), a non-psychotropic cannabinoid produced by the genus Cannabis, is a phytoceutical that activates the endocannabinoid system (ECS) through binding to CB1 and CB2 receptors. The ECS is involved in cellular homeostasis and regulates metabolic processes in virtually all mammalian tissues. Published studies on CBD focus, inter alia, on its use in prophylaxis and as an anti-inflammatory agent. Here the authors present a critical assessment of the effects of CBD on inflammatory periodontal diseases caused by bacterial virulence factors, and evaluate critically the possible benefits and drawbacks of CBD use in dentistry. Particular attention is paid to the interaction of CBD with microbially colonized oral tissues, the inflammatory response in relation to the immune response, and the destruction/regeneration of hard and soft tissues of the periodontium.

Keywords: CB1/2 receptors; bacterial virulence; cannabidiol; endocannabinoid system; gingivitis; immune system; microbial colonisation; periodontitis.

Publication types

  • Review

MeSH terms

  • Analgesics
  • Animals
  • Cannabidiol* / metabolism
  • Cannabidiol* / pharmacology
  • Cannabidiol* / therapeutic use
  • Cannabinoids*
  • Humans
  • Mammals / metabolism
  • Periodontal Diseases* / drug therapy
  • Receptor, Cannabinoid, CB1


  • Analgesics
  • Cannabinoids
  • Receptor, Cannabinoid, CB1
  • Cannabidiol